Cannabis
Why Tilray Shares Rose This Friday Morning
Tilray closed the third quarter of 2022 with revenues of $151.87 million. In the previous quarter, the company had recorded revenues of $123.9 million. The proceeds were lower than expected by analysts, the expert estimates had previously amounted to $156 million. On October 6th, 2022, Tilray is expected to provide investors with a look at its Q1 2023 financial statement.
Cannabis company Tilray has announced its key figures for the fourth quarter of fiscal 2022. Accordingly, the EPS amounted to -$0.90. After Tilray wrote earnings per share of $0.38 in the year-ago quarter, expert forecasts were for a loss of $0.079 per share for the year-to-date quarter.
Meanwhile, revenues rose to $153.33 million from $142.2 million a year earlier. That topped analysts’ estimates of $151 million for the cannabis company. Tilray shares were trading 11.72 percent higher at $4.67 in NASDAQ trading.
Read more about Tilray and find the most interesting cannabis news from around the world with the Hemp.im mobile app.
Among the most successful stocks of the day was Tilray shares
Tilray shares climbed to $3.96 (€3.89) at the peak. At the start of XETRA trading, the stock was trading at $3.96 (€3.89). So far during the day, 4 Tilray (ex Aphria) shares have been traded.
On August 11, 2021, the stock rose to its current 52-week high of $13.1 (€12.88). Gains of 69.77 percent would lift the paper to the 52-week high. On 06/16/2022, the share price decreased to as low as $2.94 (€2.89), marking the current 52-week low. Currently, Tilray (ex Aphria) shares are thus trading 34.97 percent above the 52-week low.
On July 28th, Tilray commented on its key performance indicators for the quarter that ended on May 31st
For the most recent quarter, the company reported EPS of -$0.90 per share. A year earlier, Tilray had EPS of -$0.02 on its books. Tilray ended last quarter with total revenue of $169.16. This equates to a 199.07 percent increase in revenue compared to the same quarter last year, when it earned $56.56.
Tilray closed the third quarter of 2022 with revenues of $151.87 million. In the previous quarter, the company had recorded revenues of $123.9 million. The proceeds were lower than expected by analysts, the expert estimates had previously amounted to $156 million.
On October 6th, 2022, Tilray is expected to provide investors with a look at its Q1 2023 financial statement. Experts forecast a loss of -$0.212 per Tilray share for 2023.
__
(Featured image by PublicDomainPictures via Pixabay)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in finanzen.net, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
-
Biotech1 week ago
Laminar Pharma Raises 5.9 Million in a New Round of Financing
-
Crypto11 hours ago
Bitcoin ETF Options Debut in the U.S.: Is a New All-Time High on the Horizon?
-
Biotech2 weeks ago
Leitat Purchases ReadyCell through MedTech Innovation on Advanced Medicine
-
Fintech6 days ago
Metadev3 Now Becomes a Validator on Tezos